This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek As Vice-President Of Commercialization For Its Ophthalmology Division

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology.

In his role leading commercialization activities for Imprimis's two lead ophthalmic compounded formulations, Saharek will be chiefly responsible for the "Go Dropless" marketing campaign and related outreach to leading ophthalmologists in the US and abroad.  Imprimis's first compounded formulation is a combination of two or more of Triamcinolone + Moxifloxicin + Vancomycin as an injectable solution.  What makes Imprimis's patent-pending formulation unique is that these formulations are in an injectable solution that can be administered during certain eye surgeries.  No mixing, shaking or adding anything – simply draw and inject.  Imprimis's second compounded drug formulation is a patent-pending lyophilized Epinephrine + Lidocaine or Phenylephrine + Lidocaine.  Imprimis believes these formulations, which are easily reconstituted prior to injection, will offer eye surgeons a stable and reliable source of known mydriatic agents.  In an effort to create awareness about these formulations, Imprimis will soon debut its "Go Dropless" campaign which will encourage ophthalmologists to consider reducing dependence on post-op eye drops, freeing their patients from the expense and inconvenience of eye drops and to simplify their lives with less pharmacy and more control.

"John is an experienced ophthalmology industry leader with a 25 year track record of delivering results to a range of leading companies," said Mark L. Baum, Chief Executive Officer of Imprimis. "John will complete the build out of our commercialization team and will drive our market awareness activities for our innovative ophthalmology solutions.  We are pleased to continue to add new, high-caliber individuals like John to the Imprimis team as we focus on execution and delivering results for our shareholders."

"I am excited to join the Imprimis team, to be able to lead our commercialization efforts at this exciting time," said Saharek. "So many innovative treatments are being developed for patients through the clinical interaction between pharmacists and physicians. It is an honor to help Imprimis take its unique patent-pending innovations to a broader set of patients across the country. Patients deserve and expect personalized medicine. We can deliver that care in a way that serves our patients, our physician and pharmacist partners, and our shareholders."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs